TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma
Purpose To evaluate the prevalence of two recurrent somatic mutations (−124 C>T and −146 C>T) within the promoter of the gene encoding telomerase reverse transcriptase ( TERT ) as well as their relationship with TERT level, telomeres length, and outcome in patients with head and neck squamous...
Uložené v:
| Vydané v: | Journal of cancer research and clinical oncology Ročník 146; číslo 2; s. 381 - 389 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.02.2020
Springer Nature B.V |
| Predmet: | |
| ISSN: | 0171-5216, 1432-1335, 1432-1335 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Shrnutí: | Purpose
To evaluate the prevalence of two recurrent somatic mutations (−124 C>T and −146 C>T) within the promoter of the gene encoding telomerase reverse transcriptase (
TERT
) as well as their relationship with
TERT
level, telomeres length, and outcome in patients with head and neck squamous cell carcinomas (HNSCCs).
Methods
We evaluate the prevalence of
TERT
promoter mutations,
TERT
levels, and telomere length in paired cancer tissue and adjacent mucosa (AM) in a series of HNSCCs.
Results
Cancer tissue and AM specimens from 105 patients were analyzed
.
Telomere length and
TERT
mRNA levels were estimated using real-time polymerase chain reaction.
TERT
promoter mutations were assessed using Sanger sequencing. Out of 105 cases, 101 were considered suitable for the analysis.
TERT
promoter harbored mutations in 12 tumors (11.9%), with −124 C>T and −146 C>T accounting for 83.3% and 16.7% of the alterations, respectively. No mutations were detected in AM samples. The prevalence of
TERT
promoter mutations was significantly higher in oral cavity SCCs (10 out of 27 tumors; 37%), and telomere length in AM was shorter in patients with tumors carrying
TERT
promoter mutations than in patients with unmutated
TERT
promoter cancers (
p
= 0.023).
TERT
levels in tumor did not significantly differ according to the mutational status of
TERT
promoter. No significant association was found between
TERT
promoter status and overall survival.
Conclusion
TERT
promoter mutations are most likely a late event in tumor development, occurring in a context of critically short telomeres, mostly in patients with oral cavity SCC.
TERT
levels, but not
TERT
promoter mutational status impact clinical outcome. |
|---|---|
| Bibliografia: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ISSN: | 0171-5216 1432-1335 1432-1335 |
| DOI: | 10.1007/s00432-020-03130-z |